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stereotyped as a male disease, men display a high
degree of ignorance and avoidance of both coronary
heart disease and the risk factors associated with it. For
instance, though women may avoid considering their
risk of developing coronary heart disease by assuming
it is a male disease, men too delay in seeking medical
help when experiencing chest pain.5 14 Thus coronary
heart disease is the greatest cause of premature death
in men, yet it is relatively unresearched from the
perspective of men’s health behaviour.
Though the aims as set out in the national service
framework are laudable, the fact that the framework
does not include male and female specific standards
makes it harder to create the environment for research
and health strategy development that addresses men
and women’s separate needs. This is already evident by
the relative dearth of social research into gender and
coronary heart disease. Both women’s health
groups and the Men’s Health Forum (www.
men’shealthforum.org.uk) have noted that only a few
practitioners have set up gender sensitive initiatives.
Gender must be seen as an important factor in
health care planning and delivery. Coronary heart dis›
ease is a prime example of where there are known
gender differences. We need investment in research
and inclusion of gender within educational pro›
grammes, without which health professionals will
remain ignorant of the problems created by gender
neutral health care.
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Prophylactic treatment of anthrax with antibiotics
Indiscriminate use of antibiotics will lead to resistance in organisms
Bacillus anthracis has long been considered apotential biological weapon. The Scottish islandof Gruinard was contaminated with spores for 45
years and the Aum Shinrikyo terrorists made unsuccess›
ful attempts to release aerosols of anthrax and
Clostridium botulinum spores in Tokyo.1 In addition,
anthrax spores were inadvertently released from a
microbiological facility in Sverdlovsk in the former
Soviet Union, resulting in at least 79 people getting
anthrax and 68 deaths.1 In response to the recent
anthrax attacks in the United States, the US and other
governments have bought large amounts of cipro›
floxacin, and in the US many potentially exposed
individuals have started prophylactic treatment. Unoffi›
cial use of ciprofloxacin will be common in the light of
the worldwide panic. Ciprofloxacin has been chosen to
treat anthrax for its ease of administration, good safety
profile, and predictable activity. The alternatives are
amoxicillin or doxycycline, but these too have side effects
and can induce resistance. The important thing is to
ensure that prophylactic treatment is given only to those
who really need it, and to discourage its mass use by an
understandably alarmed public. Indiscriminate use of
antibiotics can induce resistance in B anthracis and other
organisms. To induce antimicrobial resistance on a mass
scale would be an even greater triumph for the terrorists.
Anthrax is a zoonosis, accidentally transmitted
from herbivores to humans with no onward person to
person transmission. The clinical presentation and
outcome depend on the route by which anthrax is
acquired.1 Cutaneous anthrax, which is the commonest
form (95% of patients), follows inoculation of spores
into damaged skin and has the best outcome, with less
than 1% mortality. Eating badly cooked meat contami›
nated with anthrax spores leads to oropharyngeal or
gastrointestinal anthrax. This is the least common form
but has a high mortality. Inhalation of spores leads to
pulmonary anthrax, which is usually fatal.
B anthracis, including the strains isolated from the
recent cases in the US, is sensitive in vitro to a range of
antimicrobials, including penicillin, amoxicillin, doxy›
cycline, tetracycline, clarithromycin, clindamycin, and
ciprofloxacin. Benzylpenicillin is the treatment of
choice, but treating anthrax after inhalation of spores is
particularly difficult since the disease progresses
rapidly to death. This has led to the introduction of
chemoprophylaxis for individuals at risk.1 2
In animal models, penicillin, ciprofloxacin, or doxy›
cycline given 24 hours after exposure to a lethal aero›
sol provided significant protection against death, but
combining antimicrobials with vaccination provided
optimal protection.3 Currently oral ciprofloxacin is
recommended after known exposure to spores.1 2
Disease can present 50 days or more after exposure,1
so prophylaxis should continue for 60 days unless
exposure has been excluded.
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Using antimicrobials prophylactically could induce
side effects in users and resistance in bacteria. Anti›
microbials need to be used according to national
guidelines after appropriate assessment of risk,1 2 espe›
cially when such prolonged use is intended. Although
generally safe, ciprofloxacin is associated with rupture
of tendons and neuropsychiatric disorders, especially
in elderly people.4 5 In most countries it is not licensed
for use in pregnancy or children. In children the
concern is damage to the cartilage in weight bearing
joints—seen when treating juvenile beagle dogs.
This concern has not been realised yet,6 although treat›
ment for 60 days will have been used in only a small
number of patients with cystic fibrosis. Few data exist
on use of ciprofloxacin in pregnancy, and here amoxi›
cillin might be safer.
Fluoroquinolones such as ciprofloxacin are useful
drugs with broad spectrum bactericidal activity. Their
value has already been compromised by the develop›
ment of resistance through overuse.7 Humans have a
rich and varied normal bacterial flora—only 10% of the
cells we carry are human. With antimicrobials our
expectation is that the infecting pathogen will be killed,
but the myriad normal bacteria are also exposed. For
example, ciprofloxacin is excreted on to skin and
mucous membranes, and strains of Staphylococcus
epidermidis resistant to ciprofloxacin have appeared on
skin at a mean of 2.7 days after start of treatment8; they
showed co›resistance to many other classes of
antimicrobial.
Treatment with fluoroquinolone is also associated
with development of resistance in enteric coliforms9
and oral viridans streptococci.10 The new fluoroqui›
nolones (for example, levafloxacin, moxifloxacin, gati›
floxacin) have a spectrum that includes Streptococcus
pneumoniae and are used as empirical treatment in
bacterial pneumonia. They too are part of the normal
flora, and similar mutations that induce resistance to
ciprofloxacin induce resistance to the new agents. Str
pneumoniae is highly transformation competent, and
our current problems with penicillin resistant
pneumococci have resulted from acquisition of
mosaic resistance genes from commensal viridans
streptococci. Similar transfer of resistance to fluoro›
quinolones has been described in pneumococci.11 This
raises the possibility of fluoroquinolone resistance
arising in some pneumococci or viridans streptococci
during prophylaxis with ciprofloxacin, which could
then spread horizontally to other perhaps more viru›
lent pneumococci.
We have little information on the stability of such
resistance once treatment with ciprofloxacin has
stopped, but in vitro, ciprofloxacin resistant clinical iso›
lates of S aureus have retained resistance for over 500
generations in antibiotic›free media.12 Prolonged
administration of ciprofloxacin to many individuals
may lead to emergence of resistance in commensal
bacteria which could be stable and transferable to
other potentially pathogenic bacteria, thus limiting the
usefulness of these important antimicrobials. Finally,
we cannot exclude the possibility of the development
of fluoroquinolone resistance in B anthracis—multidrug
efflux pumps have already been detected in B subtilis.13
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School based programmes on obesity
Increase knowledge about nutrition but do not change eating habits by much
The prevalence of obesity has increaseddramatically in the past 20 years, and theWorld Health Organization has declared obes›
ity a global epidemic.1 The increase in prevalence of
childhood overweight and obesity is a particular
worry. To combat this epidemic, educational pro›
grammes and policies in schools would seem to be a
logical response. Two articles by Sahota et al in this
issue examine the Active Programme Promoting Life›
style Education in School, which was instituted in 10
schools in Leeds, England, over one year (pp 1027,
1029).2 3 Their result reveal a paradox: cooperation by
parents, teachers, administrators, and children was
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